181 related articles for article (PubMed ID: 25396679)
1. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
3. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
4. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
[TBL] [Abstract][Full Text] [Related]
5. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
6. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
7. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
[TBL] [Abstract][Full Text] [Related]
8. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
[TBL] [Abstract][Full Text] [Related]
9. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
Seike M; Yanaihara N; Bowman ED; Zanetti KA; Budhu A; Kumamoto K; Mechanic LE; Matsumoto S; Yokota J; Shibata T; Sugimura H; Gemma A; Kudoh S; Wang XW; Harris CC
J Natl Cancer Inst; 2007 Aug; 99(16):1257-69. PubMed ID: 17686824
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
[TBL] [Abstract][Full Text] [Related]
11. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.
Leeman JE; Rimner A; Montecalvo J; Hsu M; Zhang Z; von Reibnitz D; Panchoo K; Yorke E; Adusumilli PS; Travis W; Wu AJ
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):138-145. PubMed ID: 27839909
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
Yamauchi Y; Safi S; Muley T; Warth A; Herth FJF; Dienemann H; Hoffmann H; Eichhorn ME
Lung Cancer; 2017 Dec; 114():62-67. PubMed ID: 29173768
[TBL] [Abstract][Full Text] [Related]
13. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
Robinson BM; Kennedy C; McLean J; McCaughan BC
J Thorac Oncol; 2011 Oct; 6(10):1691-6. PubMed ID: 21869717
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
15. Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma.
Xu S; Xi J; Jiang W; Lu S; Wang Q
Ann Thorac Surg; 2015 Mar; 99(3):961-7. PubMed ID: 25633461
[TBL] [Abstract][Full Text] [Related]
16. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
17. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
Raz DJ; Ray MR; Kim JY; He B; Taron M; Skrzypski M; Segal M; Gandara DR; Rosell R; Jablons DM
Clin Cancer Res; 2008 Sep; 14(17):5565-70. PubMed ID: 18765549
[TBL] [Abstract][Full Text] [Related]
18. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
[TBL] [Abstract][Full Text] [Related]
20. Influence of cigarette smoking on survival and tumor invasiveness in clinical stage IA lung adenocarcinoma.
Maeda R; Yoshida J; Ishii G; Hishida T; Nishimura M; Nagai K
Ann Thorac Surg; 2012 May; 93(5):1626-32. PubMed ID: 22421592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]